Edwards Lifesciences Corp Stock Price, News & Analysis

Edwards Lifesciences (NYSE: EW) announced strategic investments aimed at expanding its structural heart portfolio through the acquisition of JenaValve Technology and Endotronix. The company aims to strengthen its leadership in heart innovation and address large unmet patient needs.

JenaValve Technology specializes in transcatheter treatments for aortic regurgitation (AR), a deadly and largely untreated condition. Edwards expects FDA approval for the JenaValve Trilogy Heart Valve System in late 2025.

Endotronix, a leader in heart failure (HF) management, recently received FDA approval for Cordella, an implantable pulmonary artery pressure sensor. A CMS national coverage determination is anticipated in early 2025.

The acquisitions, valued at approximately $1.2 billion, are expected to provide minimal revenue contribution in 2025 and are subject to antitrust and foreign investment approvals.

Edwards Lifesciences (NYSE: EW) reported Q2 2024 financial results. Total sales grew 7%, with TAVR sales up 5%, and TMTT sales jumping 75%. Adjusted EPS was $0.70. The company expects full-year sales growth of 8-10%, but lowered TAVR guidance to 5-7%. TMTT guidance increased to the higher end of $320-$340 million. The sale of Critical Care for $4.2 billion is expected to close by late Q3 2024. Surgical Structural Heart sales rose 3%, led by INSPIRIS, MITRIS, and KONECT technologies. The adjusted gross profit margin was 77.1%, and the company ended the quarter with $2.0 billion in cash and $600 million in debt. Q3 sales are forecasted at $1.56-$1.64 billion with EPS of $0.67-$0.71.

Edwards Lifesciences (NYSE: EW), a global leader in patient-focused innovations for structural heart disease and critical care monitoring, has announced its plans to release Q2 2024 operating results. The company will host an earnings conference call on July 24, 2024, at 5:00 p.m. ET, following the market close.

Investors and analysts can participate in the conference call by dialing (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the 'Investor Relations' section of the Edwards website at ir.edwards.com. This event provides an opportunity for stakeholders to gain insights into the company's financial performance and future outlook.

Edwards Lifesciences (NYSE: EW) has announced its decision to acquire Innovalve Bio Medical , an early-stage transcatheter mitral valve replacement (TMVR) company. This move follows Edwards' initial investment in Innovalve in 2017 and is based on the company's promising early clinical experience. The acquisition aims to enhance Edwards' TMVR technologies, addressing unmet structural heart patient needs and supporting long-term growth.

Innovalve will join Edwards' transcatheter mitral and tricuspid therapies (TMTT) product group. The company's SAPIEN M3 is expected to become the first approved transfemoral TMVR system in Europe by the end of 2025. Edwards believes that combining Innovalve's technologies with its own mitral expertise will expand the treatable population for TMVR. The acquisition is set to close by the end of 2024.

Edwards Lifesciences (NYSE: EW) has released five-year data from the PARTNER Trials, showcasing excellent outcomes for patients, particularly women and those with a small annulus, undergoing transcatheter aortic valve replacement (TAVR) using the SAPIEN 3 valve.

The analysis included over 1,300 low and intermediate risk patients and demonstrated favorable clinical outcomes and valve durability regardless of annulus size or sex. Key findings include no link between higher 30-day mean gradients or severe prosthesis-patient mismatch (PPM) with poor long-term outcomes.

Presented at New York Valves 2024, the data highlighted low reintervention rates and high five-year survival rates, reinforcing the reliability of the SAPIEN 3 valve platform for diverse patient groups.

Edwards Lifesciences announced the sale of its Critical Care product group to BD (Becton, Dickinson and Company) for $4.2 billion in cash. The transaction will enhance Edwards' financial flexibility and enable strategic investments in structural heart disease technologies. The deal is expected to close by the end of 2024, pending regulatory approvals. Edwards aims to focus on advancing innovations in aortic, mitral, tricuspid, and pulmonic treatments. The sale is anticipated to have an immaterial impact on adjusted EPS in 2024.

BD (Becton, Dickinson and Company) has announced an agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. This acquisition aims to expand BD's portfolio of smart connected care solutions and enhance its position in advanced monitoring technologies.

Critical Care, a global leader in advanced patient monitoring, generated over $900 million in revenue in 2023 and employs approximately 4,500 people. The acquisition is expected to be immediately accretive to BD's revenue growth, adjusted gross and operating margins, and adjusted earnings per share.

Critical Care will operate as a separate business unit within BD's Medical segment and will continue to be based in Irvine, California, under the leadership of Katie Szyman. The transaction is expected to close by the end of the calendar year, subject to regulatory reviews and closing conditions.

BD plans to fund the acquisition with a combination of $1 billion in cash and $3.2 billion in new debt. The company expects to achieve additional margin expansion and value through cost synergies and efficiencies.

Edwards Lifesciences has launched the SAPIEN 3 Ultra RESILIA valve in Europe, incorporating breakthrough RESILIA tissue technology for enhanced durability. The valve received CE Mark for patients with heart valve disease, with RESILIA tissue offering potential for extended durability. The valve aims to improve quality of life and future treatment options with lower rates of paravalvular leak and larger effective orifice areas. The technology is backed by 7-year COMMENCE Study data showing excellent outcomes. RESILIA tissue is a result of 20 years of research, indicating Edwards' focus on patient-centric technology.